City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Przemyslaw Twardowski, MD  
Search results:  6  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-6 Trials Jump to page:

COH Protocol Number: 16126

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Institutional

Title:  Assessment of Myeloid Derived Suppressor Cells (MDSC), in Blood of Patients with Localized or Recurrent or Metastatic Prostate Cancer

COH Protocol Number: 15113 ClinicalTrials.gov Number: NCT02286921

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: NCI Approved External Peer Review

Title:  A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer

COH Protocol Number: 14256 ClinicalTrials.gov Number: NCT02215096

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Industrial

Title:  A Phase I, Open-Label, Dose-Finding Study of GSK2636771 Administered in Combination with Enzalutamide (Xtandi) in Male Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

COH Protocol Number: 14244 ClinicalTrials.gov Number: NCT01949337

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Cooperative Group

Title:  Alliance A031201: Phase III Trial of Enzalutamide (NSC #766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

COH Protocol Number: 14201 ClinicalTrials.gov Number: NCT02059213

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Institutional

Title:  A Randomized Phase II Study of Androgen Deprivation Therapy with or without PD 0332991 in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer

COH Protocol Number: 13178 ClinicalTrials.gov Number: NCT01809691

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Cooperative Group

Title:  SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

 
Results per page: 25 50 100 All 1-6 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.